Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis

doi:10.13105/wjma.v8.i1.27

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 1

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10897)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

388

WORD

358

HTML

5866

Figures (1-5)

766

Tables (1-1)

658

Sum=8036

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1014

Download

1848

Sum=2862

Feb 28, 2020 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Meta-Analysis

World J Meta-Anal. Feb 28, 2020; 8(1): 27-40
Published online Feb 28, 2020. doi: 10.13105/wjma.v8.i1.27

Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis

Hong-Tao Fu, Ying-Ying Xu, Jing-Jing Tian, Jia-Xin Fu, Shao-Ling Nie, Yan-Yan Tang, Ping Chen, Liang Zong

Hong-Tao Fu, Department of Clinical Medicine, University of South China, Hengyang 421000, Hunan Province, China

Ying-Ying Xu, Department of General Surgery, Yizheng People’s Hospital, Yangzhou University, Yangzhou 225000, Jiangsu Province, China

Jing-Jing Tian, Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China

Jia-Xin Fu, Ping Chen, Liang Zong, Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou 225000, Jiangsu Province, China

Shao-Ling Nie, Yan-Yan Tang, Department of Colorectal Surgery, Hunan Cancer Hospital, Central South University, Changsha 410000, Hunan Province, China

Author contributions: Fu HT, Xu YY, Tian JJ and Fu JX contributed equally to this work; Zong L and Nie SL were responsible for the conception and design of the study; Fu HT, Tian JJ, Xu YY and Fu JX collected the data and organized data extraction sheets; Fu HT and Tian JJ statistically analyzed the data; Fu HT drafted the manuscript, with critical revision being performed by Zong L and Nie SL.

Conflict-of-interest statement: The authors have no conflicts of interest for this manuscript.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Corresponding author: Liang Zong, PhD, Doctor, Professor, Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou 225000, Jiangsu Province, China. 250537471@qq.com

Received: June 22, 2019
Peer-review started: June 24, 2019
First decision: August 27, 2019
Revised: September 26, 2019
Accepted: October 20, 2019
Article in press: October 20, 2019
Published online: February 28, 2020
Processing time: 252 Days and 8.4 Hours

Abstract

BACKGROUND

Many clinical studies for the long-term survival or efficacy of capecitabine plus oxaliplatin (XELOX) in colon cancer have already been studied, but its clinical benefit is controversial.

AIM

To evaluate the long-term efficacy of XELOX regimen in comparison with other adjuvant chemotherapy protocols in colon cancer.

METHODS

By searching the PubMed, EMBASE and Cochrane databases, a total of 12 randomized controlled trials involving 6698 stage III colon cancer cases (XELOX protocol: n = 3298 cases; other adjuvant chemotherapy protocol: n = 3268 cases) were included. The parameter outcomes included the overall survival and the disease-free survival. The quality control of selected literature was based on the Jadad scale and the GRADE system.

RESULTS

In comparison to other adjuvant chemotherapy regimen, XELOX regimen showed a better overall survival (odds ratio = 1.29, 95% confidence interval: 1.15-1.44, P < 0.0001) and a better disease-free survival (odds ratio = 1.32, 95% confidence interval: 1.18-1.46, P < 0.0001) for colon cancer patients, suggesting the XELOX regimen can be a good option for postoperative treatment of stage III colon cancer.

CONCLUSION

The XELOX regimen can be a preferred option for adjuvant treatment of stage III colon cancer after surgery.

Keywords: Capecitabine plus oxaliplatin chemotherapy; Colon cancer; Meta-analysis; Long-term effect

Core tip: Many clinical studies for the long-term survival of patients or the efficacy of capecitabine plus oxaliplatin (XELOX) in colon cancer have already been studied, but its clinical benefit is controversial. The long-term efficacy of the XELOX regimen in comparison with other adjuvant chemotherapy protocols in colon cancer was evaluated. By searching the PubMed, EMBASE and Cochrane databases, a total of 12 randomized controlled trials involving 6698 stage III colon cancer cases were included. Our findings showed that XELOX regimen had a better overall survival and a better disease-free survival. The XELOX regimen can be a preferred option for adjuvant treatment of stage III colon cancer after surgery.